Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Section 3. A Discussion of Flexible Dosing and Patient-Centered Therapy: Highlights of the Asthma Summit 2009: Beyond the Guidelines

Section 3. A Discussion of Flexible Dosing and Patient-Centered Therapy: Highlights of the Asthma... Despite positive clinical experience and the published clinical benefits of monotherapy with low-or medium-dose inhaled corticosteroids or combination therapy with ICS + long-acting beta-agonist to treat asthma, many patients remain suboptimally controlled. Alternative approaches are needed, and 3 options that have had some success are: 1) using the patient's level of inflammation by established biomarkers to set treatment; 2) self-management incorporating flexible dosing; and 3) using a single inhaler for rescue and maintenance therapy. Which strategy for which patient depends ultimately on the individual patient's disease burden, life-style, comorbidities, preferences, and his or her ability to self-manage the disease, including assessing symptoms and adhering with therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png World Allergy Organization Journal Springer Journals

Section 3. A Discussion of Flexible Dosing and Patient-Centered Therapy: Highlights of the Asthma Summit 2009: Beyond the Guidelines

Loading next page...
 
/lp/springer-journals/section-3-a-discussion-of-flexible-dosing-and-patient-centered-therapy-Nh2tRQsOeK

References (70)

Publisher
Springer Journals
Copyright
Copyright © 2010 by World Allergy Organization; licensee BioMed Central Ltd.
Subject
Medicine & Public Health; Allergology; Immunology
eISSN
1939-4551
DOI
10.1097/WOX.0b013e3181d27cd8
pmid
24228889
Publisher site
See Article on Publisher Site

Abstract

Despite positive clinical experience and the published clinical benefits of monotherapy with low-or medium-dose inhaled corticosteroids or combination therapy with ICS + long-acting beta-agonist to treat asthma, many patients remain suboptimally controlled. Alternative approaches are needed, and 3 options that have had some success are: 1) using the patient's level of inflammation by established biomarkers to set treatment; 2) self-management incorporating flexible dosing; and 3) using a single inhaler for rescue and maintenance therapy. Which strategy for which patient depends ultimately on the individual patient's disease burden, life-style, comorbidities, preferences, and his or her ability to self-manage the disease, including assessing symptoms and adhering with therapy.

Journal

World Allergy Organization JournalSpringer Journals

Published: Feb 15, 2010

There are no references for this article.